d-serine as a metabolic immune checkpoint in the tumour microenvironment.
A naturally occurring molecule controls immune suppression in gut tumors, offering a fresh therapeutic target grounded in the microenvironment.
D-serine, a D-amino acid enantiomer, functions as a novel metabolic immune checkpoint in gastrointestinal cancers; modulates the tumor immune microenvironment via macrophage-T cell interactions and microbiome-dependent pathways, with clinical correlates in GI cancer patients. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- translational (scRNA-seq + flow cytometry + organoid allografts + microbiome manipulation)
- Category
- novel_therapeutics
- Maturity
- Exploratory
- Journal
- EBioMedicine
Why it surfaced
Entirely novel class of metabolic immune checkpoints (D-amino acids) with multi-modal preclinical validation and clinical correlates; EBioMedicine (high-impact OA Lancet journal); dual relevance to immunotherapy optimization and tumor-microbiome interactions in GI cancers—major growth area.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.